Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2021 Filed Mar 17, 2021 20:38 UTC |
TAI JACKSON PDirector
|
GrantCommon Stock | 10 | $189.16 | $1,891.60 |
DisclosureSEC source: 0000059478-21-000098 · wf-form4_161601346433205.xml · nonDerivative · entry 1 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,819 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 20:41 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 58 | $189.16 | $10,971.28 |
DisclosureSEC source: 0000059478-21-000100 · wf-form4_161601369690417.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,459 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 19:59 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 1,726 | $211.90 | $365,741.13 |
DisclosureSEC source: 0001209191-21-019413 · doc4.xml · nonDerivative · entry 4 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,302,100 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.82 to $212.04, inclusive. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 19:59 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 7,720 | $211.13 | $1,629,946.76 |
DisclosureSEC source: 0001209191-21-019413 · doc4.xml · nonDerivative · entry 3 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,303,826 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.80 to $211.60, inclusive. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 19:59 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 17,270 | $210.28 | $3,631,501.06 |
DisclosureSEC source: 0001209191-21-019413 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,311,546 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.80 to $210.77, inclusive. Read SEC document |
| March 09, 2021 Filed Mar 10, 2021 19:59 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 33,243 | $209.12 | $6,951,842.65 |
DisclosureSEC source: 0001209191-21-019413 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,328,816 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.80 to $209.79, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3) and (4) to this Form 4. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 17:26 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 60,874 | $210.12 | $12,790,723.13 |
DisclosureSEC source: 0001209191-21-018870 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,362,059 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $209.8037 to $210.7578, inclusive. Read SEC document |
| March 08, 2021 Filed Mar 9, 2021 17:26 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 64,410 | $209.29 | $13,480,368.90 |
DisclosureSEC source: 0001209191-21-018870 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,422,933 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $208.80 to $209.79, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:19 UTC |
Hakim AnatSVP, GC & Secretary
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,928 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000094 · wf-form4_161480994384681.xml · derivative · entry 3 Hakim Anat · CIK 0001685556 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,929 Underlying: Common Stock · 7,928 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in two installments, 7,928 on March 1, 2021 and 7,929 on March 1, 2022. F2 · derivative.expiration_date: The Restricted Stock Units vest in two installments, 7,928 on March 1, 2021 and 7,929 on March 1, 2022. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:19 UTC |
Hakim AnatSVP, GC & Secretary
|
Tax withholdingCommon Stock | 3,493 | $204.89 | $715,680.77 |
DisclosureSEC source: 0000059478-21-000094 · wf-form4_161480994384681.xml · nonDerivative · entry 2 Hakim Anat · CIK 0001685556 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,435 Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:19 UTC |
Hakim AnatSVP, GC & Secretary
|
Exercise / conversionCommon Stock | 7,928 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000094 · wf-form4_161480994384681.xml · nonDerivative · entry 1 Hakim Anat · CIK 0001685556 · SVP, GC & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:26 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 53 | $207.76 | $11,011.28 |
DisclosureSEC source: 0000059478-21-000086 · wf-form4_161368359149440.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,198 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:29 UTC |
TAI JACKSON PDirector
|
GrantCommon Stock | 10 | $205.76 | $2,057.60 |
DisclosureSEC source: 0000059478-21-000088 · wf-form4_161368376930201.xml · nonDerivative · entry 1 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,750 F1 · shares: At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:27 UTC |
Ashkenazi AnatSVP & CFO
|
GrantCommon Stock | 7,975 | $205.77 | $1,641,015.75 |
DisclosureSEC source: 0000059478-21-000042 · wf-form4_161300682800162.xml · nonDerivative · entry 1 Ashkenazi Anat · CIK 0001761679 · SVP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,675 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:29 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantRestricted Stock Unit · Derivative | 4,014 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000044 · wf-form4_161300696896190.xml · derivative · entry 3 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,014 Underlying: Common Stock · 4,014 shares Expires 2022-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:29 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
GrantCommon Stock | 9,594 | $205.77 | $1,974,157.38 |
DisclosureSEC source: 0000059478-21-000044 · wf-form4_161300696896190.xml · nonDerivative · entry 1 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,616 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:31 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantRestricted Stock Unit · Derivative | 10,170 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000046 · wf-form4_161300706667100.xml · derivative · entry 3 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,170 Underlying: Common Stock · 10,170 shares Expires 2022-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:31 UTC |
Fry Stephen FSVP, HR & Diversity
|
GrantCommon Stock | 26,133 | $205.77 | $5,377,387.41 |
DisclosureSEC source: 0000059478-21-000046 · wf-form4_161300706667100.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,676 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:32 UTC |
Jonsson PatrikSVP & President Lilly USA
|
GrantCommon Stock | 5,595 | $205.77 | $1,151,283.15 |
DisclosureSEC source: 0000059478-21-000048 · wf-form4_161300715740126.xml · nonDerivative · entry 1 Jonsson Patrik · CIK 0001786054 · SVP & President Lilly USA 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,674 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:34 UTC |
Mason Michael BSr. VP & Pres., Lilly Diabetes
|
GrantCommon Stock | 6,350 | $205.77 | $1,306,639.50 |
DisclosureSEC source: 0000059478-21-000050 · wf-form4_161300725044581.xml · nonDerivative · entry 1 Mason Michael B · CIK 0001799419 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,894 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:36 UTC |
Norton JohnaSenior VP, Global Quality
|
GrantRestricted Stock Unit · Derivative | 2,676 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000052 · wf-form4_161300734811911.xml · derivative · entry 5 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,676 Underlying: Common Stock · 2,676 shares Expires 2022-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:36 UTC |
Norton JohnaSenior VP, Global Quality
|
GrantCommon Stock | 6,040 | $205.77 | $1,242,850.80 |
DisclosureSEC source: 0000059478-21-000052 · wf-form4_161300734811911.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,464 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:37 UTC |
O'Neill MylesSVP & Pres., Mfg. Operations
|
GrantRestricted Stock Unit · Derivative | 8,565 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000054 · wf-form4_161300744414496.xml · derivative · entry 4 O'Neill Myles · CIK 0001725140 · SVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,565 Underlying: Common Stock · 8,565 shares Expires 2022-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:37 UTC |
O'Neill MylesSVP & Pres., Mfg. Operations
|
GrantCommon Stock | 21,052 | $205.77 | $4,331,870.04 |
DisclosureSEC source: 0000059478-21-000054 · wf-form4_161300744414496.xml · nonDerivative · entry 1 O'Neill Myles · CIK 0001725140 · SVP & Pres., Mfg. Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,533 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:39 UTC |
Pusey Leigh AnnSVP, Corp. Affairs & Comm.
|
GrantRestricted Stock Unit · Derivative | 4,416 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000056 · wf-form4_161300753846399.xml · derivative · entry 2 Pusey Leigh Ann · CIK 0001708919 · SVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,416 Underlying: Common Stock · 4,416 shares Expires 2022-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:39 UTC |
Pusey Leigh AnnSVP, Corp. Affairs & Comm.
|
GrantCommon Stock | 10,791 | $205.77 | $2,220,464.07 |
DisclosureSEC source: 0000059478-21-000056 · wf-form4_161300753846399.xml · nonDerivative · entry 1 Pusey Leigh Ann · CIK 0001708919 · SVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,529 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:41 UTC |
Ricks David ADirector · President & CEO
|
GrantRestricted Stock Unit · Derivative | 56,205 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000058 · wf-form4_161300764206200.xml · derivative · entry 3 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,205 Underlying: Common Stock · 56,205 shares Expires 2022-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:41 UTC |
Ricks David ADirector · President & CEO
|
GrantCommon Stock | 130,343 | $205.77 | $26,820,679.11 |
DisclosureSEC source: 0000059478-21-000058 · wf-form4_161300764206200.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,244 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:43 UTC |
Shah Aarti S.SVP & CIDO
|
GrantRestricted Stock Unit · Derivative | 4,550 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000060 · wf-form4_161300776263267.xml · derivative · entry 3 Shah Aarti S. · CIK 0001725292 · SVP & CIDO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,550 Underlying: Common Stock · 4,550 shares Expires 2022-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:43 UTC |
Shah Aarti S.SVP & CIDO
|
GrantCommon Stock | 11,033 | $205.77 | $2,270,260.41 |
DisclosureSEC source: 0000059478-21-000060 · wf-form4_161300776263267.xml · nonDerivative · entry 1 Shah Aarti S. · CIK 0001725292 · SVP & CIDO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,622 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:44 UTC |
Skovronsky DanielSVP, CSO, and Pres. LRL
|
GrantRestricted Stock Unit · Derivative | 18,735 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000062 · wf-form4_161300786939313.xml · derivative · entry 2 Skovronsky Daniel · CIK 0001741474 · SVP, CSO, and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,735 Underlying: Common Stock · 18,735 shares Expires 2022-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:44 UTC |
Skovronsky DanielSVP, CSO, and Pres. LRL
|
GrantCommon Stock | 18,521 | $205.77 | $3,811,066.17 |
DisclosureSEC source: 0000059478-21-000062 · wf-form4_161300786939313.xml · nonDerivative · entry 1 Skovronsky Daniel · CIK 0001741474 · SVP, CSO, and Pres. LRL 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,680 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:46 UTC |
Smiley Joshua LFormer Officer
|
GrantCommon Stock | 25,409 | $205.77 | $5,228,409.93 |
DisclosureSEC source: 0000059478-21-000064 · wf-form4_161300799296197.xml · nonDerivative · entry 1 Smiley Joshua L · CIK 0001725189 · Former Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,659 F1 · security: Represents a payout of 75% of the 2018-2020 shareholder value award in connection with the Separation Agreement between Mr. Smiley and the Company dated February 8, 2021. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:48 UTC |
White Anne E.SVP & Pres-Lilly Oncology
|
GrantRestricted Stock Unit · Derivative | 9,368 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000066 · wf-form4_161300810149825.xml · derivative · entry 2 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,368 Underlying: Common Stock · 9,368 shares Expires 2022-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:48 UTC |
White Anne E.SVP & Pres-Lilly Oncology
|
GrantCommon Stock | 4,718 | $205.77 | $970,822.86 |
DisclosureSEC source: 0000059478-21-000066 · wf-form4_161300810149825.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,840 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:50 UTC |
Yuffa IlyaSVP and Pres, Lilly Bio-Meds
|
GrantCommon Stock | 3,536 | $205.77 | $727,602.72 |
DisclosureSEC source: 0000059478-21-000068 · wf-form4_161300819720563.xml · nonDerivative · entry 1 Yuffa Ilya · CIK 0001826001 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,349 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:51 UTC |
Zakrowski Donald AChief Accounting Officer
|
GrantCommon Stock | 4,247 | $205.77 | $873,905.19 |
DisclosureSEC source: 0000059478-21-000070 · wf-form4_161300828293741.xml · nonDerivative · entry 1 Zakrowski Donald A · CIK 0001561539 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,987 Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:53 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
GrantRestricted Stock Unit · Derivative | 10,706 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000072 · wf-form4_161300839694269.xml · derivative · entry 3 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,706 Underlying: Common Stock · 10,706 shares Expires 2022-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:53 UTC |
Zulueta Alfonso GSVP & President, Lilly Int'l
|
GrantCommon Stock | 29,037 | $205.77 | $5,974,943.49 |
DisclosureSEC source: 0000059478-21-000072 · wf-form4_161300839694269.xml · nonDerivative · entry 1 Zulueta Alfonso G · CIK 0001596336 · SVP & President, Lilly Int'l 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,947 Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:29 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,445 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000020 · wf-form4_161239497033708.xml · derivative · entry 4 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,445 shares Expires 2021-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:29 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
Tax withholdingCommon Stock | 2,403 | $207.97 | $499,751.91 |
DisclosureSEC source: 0000059478-21-000020 · wf-form4_161239497033708.xml · nonDerivative · entry 2 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,022 Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:29 UTC |
Barnes Melissa SChief Eth/Cmpl Ofcr & SVP, ERM
|
Exercise / conversionCommon Stock | 5,445 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000020 · wf-form4_161239497033708.xml · nonDerivative · entry 1 Barnes Melissa S · CIK 0001566364 · Chief Eth/Cmpl Ofcr & SVP, ERM 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:33 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionRestricted Stock Unit · Derivative | 15,078 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000022 · wf-form4_161239521546685.xml · derivative · entry 4 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,078 shares Expires 2021-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:33 UTC |
Fry Stephen FSVP, HR & Diversity
|
Tax withholdingCommon Stock | 6,746 | $207.97 | $1,402,965.62 |
DisclosureSEC source: 0000059478-21-000022 · wf-form4_161239521546685.xml · nonDerivative · entry 2 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,543 Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:33 UTC |
Fry Stephen FSVP, HR & Diversity
|
Exercise / conversionCommon Stock | 15,078 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000022 · wf-form4_161239521546685.xml · nonDerivative · entry 1 Fry Stephen F · CIK 0001513324 · SVP, HR & Diversity 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:38 UTC |
Norton JohnaSenior VP, Global Quality
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,435 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000024 · wf-form4_161239548901874.xml · derivative · entry 6 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,435 shares Expires 2021-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:38 UTC |
Norton JohnaSenior VP, Global Quality
|
Tax withholdingCommon Stock | 1,529 | $207.97 | $317,986.13 |
DisclosureSEC source: 0000059478-21-000024 · wf-form4_161239548901874.xml · nonDerivative · entry 2 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,424 Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:38 UTC |
Norton JohnaSenior VP, Global Quality
|
Exercise / conversionCommon Stock | 3,435 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000024 · wf-form4_161239548901874.xml · nonDerivative · entry 1 Norton Johna · CIK 0001702471 · Senior VP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:51 UTC |
Pusey Leigh AnnSVP, Corp. Affairs & Comm.
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,282 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000028 · wf-form4_161239627141009.xml · derivative · entry 3 Pusey Leigh Ann · CIK 0001708919 · SVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,282 shares Expires 2021-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 23:51 UTC |
Pusey Leigh AnnSVP, Corp. Affairs & Comm.
|
Tax withholdingCommon Stock | 2,854 | $207.97 | $593,546.38 |
DisclosureSEC source: 0000059478-21-000028 · wf-form4_161239627141009.xml · nonDerivative · entry 2 Pusey Leigh Ann · CIK 0001708919 · SVP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,738 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.